Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Senmiao Ni

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Biologics : Targets & Therapy|March 6, 2026
First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect ComparisonYi Zhu, Xiao Qi, Senmiao Ni, et al.
Cancers|August 26, 2022
The m6A-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Tumor Immune Infiltration in Ovarian CancerRui Geng, Tian Chen, Zihang Zhong, et al.
Journal of Applied Statistics|February 28, 2024
The heterogeneity effect of surveillance intervals on progression free survivalZihang Zhong, Min Yang, Senmiao Ni, et al.
Statistical Methods in Medical Research|March 29, 2024
Sample size estimation for stratified cluster randomization trial with survival endpointSenmiao Ni, Zihang Zhong, Yang Zhao, et al.
Molecular Therapy. Nucleic Acids|March 1, 2022
Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCECJinhui Liu, Rui Geng, Senmiao Ni, et al.
Biometrical Journal. Biometrische Zeitschrift|April 6, 2024
Beta spending function based on conditional power in group sequential designSenmiao Ni, Zihang Zhong, Zhiwei Jiang, et al.
Journal of Biopharmaceutical Statistics|July 6, 2022
Risk difference, relative risk, and odds ratio for non-inferiority clinical trials with risk rate endpointSenmiao Ni, Quanji Yu, Zihang Zhong, et al.
Computational and Structural Biotechnology Journal|October 17, 2022
Pyroptosis-related gene expression patterns and corresponding tumor microenvironment infiltration characterization in ovarian cancerJinhui Liu, Can Chen, Rui Geng, et al.
BMC Medical Research Methodology|April 30, 2026
Choose-NI-metric: a shiny application for converting and comparing non-inferiority metrics in binary endpoint trialsWen Liu, Senmiao Ni, Ruyu Huang, et al.
Oxidative Medicine and Cellular Longevity|August 15, 2022
N1-Methyladenosine-Related lncRNAs Are Potential Biomarkers for Predicting Prognosis and Immune Response in Uterine Corpus Endometrial CarcinomaJinhui Liu, Rui Geng, Zihang Zhong, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Biologics : Targets & Therapy|March 6, 2026
First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect ComparisonYi Zhu, Xiao Qi, Senmiao Ni, et al.
Cancers|August 26, 2022
The m6A-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Tumor Immune Infiltration in Ovarian CancerRui Geng, Tian Chen, Zihang Zhong, et al.
Journal of Applied Statistics|February 28, 2024
The heterogeneity effect of surveillance intervals on progression free survivalZihang Zhong, Min Yang, Senmiao Ni, et al.
Statistical Methods in Medical Research|March 29, 2024
Sample size estimation for stratified cluster randomization trial with survival endpointSenmiao Ni, Zihang Zhong, Yang Zhao, et al.
Molecular Therapy. Nucleic Acids|March 1, 2022
Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCECJinhui Liu, Rui Geng, Senmiao Ni, et al.
Biometrical Journal. Biometrische Zeitschrift|April 6, 2024
Beta spending function based on conditional power in group sequential designSenmiao Ni, Zihang Zhong, Zhiwei Jiang, et al.
Journal of Biopharmaceutical Statistics|July 6, 2022
Risk difference, relative risk, and odds ratio for non-inferiority clinical trials with risk rate endpointSenmiao Ni, Quanji Yu, Zihang Zhong, et al.
Computational and Structural Biotechnology Journal|October 17, 2022
Pyroptosis-related gene expression patterns and corresponding tumor microenvironment infiltration characterization in ovarian cancerJinhui Liu, Can Chen, Rui Geng, et al.
BMC Medical Research Methodology|April 30, 2026
Choose-NI-metric: a shiny application for converting and comparing non-inferiority metrics in binary endpoint trialsWen Liu, Senmiao Ni, Ruyu Huang, et al.
Oxidative Medicine and Cellular Longevity|August 15, 2022
N1-Methyladenosine-Related lncRNAs Are Potential Biomarkers for Predicting Prognosis and Immune Response in Uterine Corpus Endometrial CarcinomaJinhui Liu, Rui Geng, Zihang Zhong, et al.
Pageof 3